In fact, demand has been so high that it's been surpassing supply, forcing Lilly and rival Novo Nordisk to invest in ...

Starter doses of the weight-loss drug Zepbound are ... Patients “should not use a compounded drug if an approved drug is available,” the agency has said. Eli Lilly has also raised concerns ...

Weight loss drugs are likely to stay in demand for a long time judging by the obesity trend as shown by latest CDC data ...

(Reuters) -Eli Lilly's weight-loss drug ... at that time showed the drug helped cut weight significantly in obese patients, helping it to secure U.S. regulatory approval. It was unclear if ...

Demand for Eli Lilly’s Zepbound and Mounjaro has outstripped supply over the last year, forcing the company to invest heavily ...

The maker of blockbuster appetite-suppressing drugs Mounjaro and Zepbound is seeking to end a regulatory designation that has ...

Drug giant Eli Lilly says ... "It's a weight loss drug, but it's probably more than that," he said, citing heart disease and diabetes, for which the drugs are already approved, and potentially ...

Aug 20 (Reuters) - Eli Lilly's (LLY.N), opens new tab weight-loss drug ... showed the drug helped cut weight significantly in obese patients, helping it to secure U.S. regulatory approval.

Eli Lilly is cutting the cost of certain weight loss drugs, with new single-dose vials costing less than other medications ...

Eli Lilly’s weight-loss drug, Zepbound ... The data at that time showed the drug helped cut weight significantly in obese patients, helping it to secure US regulatory approval. It was unclear if the ...